Clinical trial • Phase I • Endocrinology
Clinical trial in Overweight | Obesity
Phase I trial for Overweight | Obesity. 102 participants.
Overview
- Trial Therapeutic Area
- Endocrinology
- Trial Disease
- Overweight | Obesity
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 03-03-2025
- First CTIS Authorization Date
- 23-06-2025
Trial design
Phase I trial across 2 sites in Romania.
- Target Sample Size
- 102
Recruitment
- Planned Sample Size
- 102
- Recruitment Window Months
- 15
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 102
Romania
- Earliest CTIS Part Ii Submission Date
- 26-05-2025
- Latest Decision Or Authorization Date
- 24-07-2025
- Processing Time Days
- 59
- Number Of Sites
- 2
- Number Of Participants
- 34
Sites
- Site Name
- Spitalul Clinic Judetean De Urgenta Cluj
- Department Name
- Ph.I Unit-AEM in collab. with County Emg. Hospital Cluj Ophthalm. build., 1st fl, wrds 33,34,35
- Contact Person Name
- Mihaela Mocan
- Contact Person Email
- mihaela.mocan.ext@arensia-em.com
- Site Name
- Arensia Clinics S.R.L.
- Department Name
- Ph. I Unit-ArensiaEM in collab. with Arensia Clinics, 3rd Floor, Wards 1,2,3,4,5,6 and 7
- Contact Person Name
- Cornelia Zetu
- Contact Person Email
- cornelia.zetu.ext@arensia-em.com
Sponsor
Primary sponsor
- Full Name
- Wave Life Sciences Ireland Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Ireland
Related trials
Other published trials that may interest you.
- survodutide for Overweight | Obesity
- CAGRILINTIDE for Overweight | Obesity
- cagrilintide (NNC0174-0833) | semaglutide (NNC0113-0217) for Overweight | Obesity
- Hydrocortisone for Glucocorticoid-induced adrenal insufficiency | Polymyalgia rheumatica | Giant cell arteritis
- ALN-4324 for Type 2 diabetes mellitus